268 results about "Phosphorylcholine" patented technology

The invention discloses a temperature / CO2 dual-response zwitterionic hydrogel profile control agent, which is prepared by taking a monomer A, a monomer B and a monomer C as raw materials, adding a cross-linking agent and an initiator, and carrying out polymerization reaction in a water medium. The monomer A is selected from any one of acrylamide, acrylic acid and 1-vinyl-2-pyrrolidone; the monomer B is selected from any one of [2-(methacryloyloxy) ethyl] dimethyl-(3-sulfopropyl) ammonium hydroxide, 2-methacryloyloxyethyl phosphorylcholine and 3-((2-(methacryloyloxy) ethyl) dimethylamino) propionic acid inner salt; and the monomer C is selected from any one of 2-(dimethylamino) ethyl methacrylate, dimethylamino propyl methacrylamide and polyethyleneimine. The profile control agent has double swelling mechanisms, has outstanding temperature and salt resistance, resists 220000 mg / L of mineralization water, is suitable for high-salt reservoirs, and is good in long-term aging property.

The invention discloses a degradable environment-friendly modified plastic master batch and a preparation method thereof, and belongs to the technical field of plastic master batches, the plastic master batch comprises the following raw materials by weight: 100 parts of polypropylene, 40-50 parts of polylactic acid, 10-20 parts of MOFs modified carbon fiber, 5-10 parts of a compatibilizer, and 1-3 parts of an antioxidant; and the compatibilizer is 2-methacryloyloxyethyl phosphorylcholine grafted polypropylene. The preparation method comprises the following steps: uniformly mixing the raw materials, and carrying out melt extrusion. Polypropylene and polylactic acid are used as basic resin, 2-methacryloyloxyethyl phosphorylcholine grafted polypropylene is used as a compatibilizer, and MOFs modified carbon fiber is used as a reinforcing material to prepare the modified plastic master batch which has good biodegradability and mechanical properties; the method has obvious performance advantages and technical competitiveness in practical application.

The invention belongs to the field of bioengineering, and particularly relates to phosphorylcholine cytidyltransferase and application thereof in preparation of citicoline, and the specific application is that the phosphorylcholine cytidyltransferase can efficiently catalyze phosphorylcholine and CTP to react to generate citicoline. The phosphorylcholine cytidyltransferase is prepared by the following steps: synthesizing a coding gene of the phosphorylcholine cytidyltransferase, selecting pHT01 as an expression vector, co-expressing with choline kinase, transforming into host bacteria, and inducing protein expression. According to the choline phosphate cytidyltransferase disclosed by the invention, under the same reaction condition and within the same reaction time, the yield of a citicoline product obtained by conversion is higher than that of choline phosphate cytidyltransferase (ScCCT) which is most commonly used in the market at present and is derived from saccharomyces cerevisiae S288c. Specifically, the yield of the MsCCT001 is 10 times higher than that of the ScCCT, the yield of the MbCCT006 is 6 times higher than that of the ScCCT, and the yield of the MeCCT008 is 8 times higher than that of the ScCCT.

The invention provides a medical hydrophilic coating and a preparation method and application thereof.The coating comprises a substrate layer and a functional layer, the substrate layer is arranged on the surface of a medical base material, the functional layer is arranged on the surface of the side, away from the medical base material, of the substrate layer, and the substrate layer comprises a substrate modification material containing a first reactive functional group; the functional layer comprises a phosphorylcholine compound containing a second reactive functional group; the substrate layer and the functional layer are connected through a chemical bond formed by the first reactive functional group and the second reactive functional group; the substrate modification material contains a third reactive functional group, and the substrate layer is connected with the medical base material through a chemical bond formed by the third reactive functional group and hydroxyl or amino on the surface of the medical base material; when the first reactive functional group is an azide group, the second reactive functional group is an alkynyl group; or when the first reactive functional group is the alkynyl group, the second reactive functional group is the azide group. Chemical bonds are formed through azido and alkynyl, multiple chemical reactions are not needed, and the uniformity of the coating is improved.

The invention discloses a phosphatidylcholine gold nano CT (Computed Tomography) probe as well as a preparation method and application thereof, and belongs to the technical field of medical materials. The preparation method comprises the following steps: step S1, preparing a phosphatidylcholine ligand NH2-MPC; step S2, synthesis of a gold nanocluster GS-Au25 is carried out; and S3, the GS-Au25 is modified with a PC ligand, and the PC-Au25 is prepared. The ultra-small gold nano CT probe PC-Au25 with an Au25 gold nano cluster as a core and phosphatidylcholine PC as a surface ligand is obtained by optimizing and screening the core size and the surface ligand property of ultra-small gold nano particles. Wherein the 2-methacryloyloxyethyl phosphorylcholine is used as a PC ligand for the first time to modify the surfaces of the ultra-small gold nanoparticles, so that the surface modification of the ultra-small gold nanoparticles is realized, and the ultra-small gold nanoparticles can be efficiently and freely filtered through the kidney. The CT probe can be applied to the determination of the glomerular filtration rate through a CT imaging or blood test method.

The invention relates to a perovskite cell with a self-assembly monomolecular layer and a preparation method, and a perovskite assembly with the self-assembly monomolecular layer is suitable for being arranged on an external substrate, and comprises a transparent conductive layer, a hole transport layer, a perovskite active layer, an electron transport layer, a hole barrier layer, a back electrode and the self-assembly monomolecular layer. Wherein the self-assembled monomolecular layer is arranged between the hole transport layer and the perovskite active layer, a solution of a precursor of the self-assembled monomolecular layer comprises phosphorylcholine chloride and Me-4PACz, and a solvent of the precursor of the self-assembled monomolecular layer is a mixed solvent of ethanol and isopropanol; according to the invention, the phosphorylcholine chloride and the Me-4PACz are introduced, so that the interface performance, the photoelectric conversion efficiency and the long-term stability of the perovskite cell are remarkably optimized.

The invention belongs to the field of nutrient substance research, and particularly relates to a nutritional composition beneficial to improvement of neural behaviors and cognition. The nutritional composition provided by the invention comprises necessary active ingredients shown in the following (i) and (ii): (i) lactose-N-neotetraose, (ii) 1, 2-diacyl-sn-glycerol-3-phosphorylcholine, and (iii) 1, 2-diacyl-sn-glycerol-3-phosphorylcholine. The nutritional composition comprises lactose-N-neotetraose and 1, 2-diacyl-sn-glycerol-3-phosphorylcholine, and in the nutritional composition, the mass ratio of the lactose-N-neotetraose to the 1, 2-diacyl-sn-glycerol-3-phosphorylcholine is 1: (0.010-2.0). The lactose-N-neotetraose and the 1, 2-diacyl-sn-glycerol-3-phosphorylcholine can achieve a synergistic effect to improve filial generation repeated engraving behaviors caused by maternal immune activation, decrease of social behavior ability and decrease of anxiety state and memory and recognition ability.

The invention relates to an enamel repair material and a preparation method thereof, and belongs to the technical field of medical filling materials for tooth defects, the enamel repair material comprises F-HAp, APTES-ZrO2, MPC modified composite resin, 10-MDP, gamma-MPS, a composite initiator, MPC and a dispersant; f-HAp is a fluorine-doped enamel-like hydroxyapatite nanorod, and F-HAp is a fluorine-doped enamel The APTES-ZrO2 is nano zirconium oxide modified by aminopropyl triethoxy silane, and the nano zirconium oxide modified by the aminopropyl triethoxy silane is The MPC modified composite resin is 2-methacryloyloxyethyl phosphorylcholine grafted and modified dimethyl acrylic acid carbamate and glycidyl methacrylate elastomer composite resin; the F-HAp, APTES-ZrO2 and MPC modified composite resin is prepared by adopting a special method, and is compounded with other components according to a certain proportion to obtain the enamel repair material, so that the enamel repair material has good cohesiveness, strength and biocompatibility and excellent leakage resistance, and the use safety and durability are improved.

The invention discloses a high-strength self-degradable gel temporary plugging agent and a preparation method thereof, and relates to the technical field of oil-gas field development. The temporary plugging agent is prepared by the following steps: firstly, reacting a diprimary amine compound with unsaturated glycidyl to prepare a multi-arm cross-linking agent, then reacting an acrylamide monomer, an acidic monomer, a rigid monomer and a 2-methacryloyloxyethyl phosphorylcholine monomer under the action of the multi-arm cross-linking agent and an initiator, and after the reaction is finished, crushing, drying and granulating to obtain the temporary plugging agent. The high-strength self-degradation gel temporary plugging agent prepared by the invention not only has relatively high strength, but also can be self-degraded, and the permeability recovery rate of a reservoir after degradation is relatively high, so that the influence on the reservoir is relatively small.

The invention belongs to the technical field of bioengineering, and particularly relates to a phosphorylcholine cytidyltransferase mutant and application thereof. On the basis of phosphorylcholine cytidyltransferase MsCCT001, any one or more of N194D, K91E, G98S, S148A and C156V are mutated respectively, a series of phosphorylcholine cytidyltransferase mutants are obtained through screening, and the obtained mutants have the advantages that in the reaction of catalyzing phosphorylcholine and cytidine triphosphate to generate citicoline, the yield of the obtained mutants is increased, and the yield of the obtained mutants is increased. The catalytic efficiency of the compound is 1.90-2.41 times that of initial phosphorylcholine cytidyltransferase, and a biological enzyme preparation with higher catalytic capacity is provided for preparing citicoline by a biological conversion method.

To provide FVIII drugs with increased in vivo half-life while retaining sufficient biological activity, and prevention methods for hemophilia subjects.SOLUTION: The invention provides a conjugate comprising recombinant FVIII (rFVIII) and a zwitterionic polymer, where the polymer comprises one or more monomer units and where at least one monomer unit comprises a zwitterionic group. Optionally, the zwitterionic group comprises phosphorylcholine. In some conjugates, the polymer is covalently bonded to at least one of an amino group, a hydroxyl group, a sulfhydryl group and a carboxyl group of rFVIII.SELECTED DRAWING: Figure 2

The invention provides a glycerophosphorylcholine-collagen peptide microcapsule and a preparation method and application thereof.The glycerophosphorylcholine-collagen peptide microcapsule takes glycerophosphorylcholine as a core material and takes a compound formed by polysaccharide containing galacturonic acid and hydrolyzed collagen peptide as a wall material, the preparation method comprises the following steps: preparing a glycerophosphorylcholine solution, activating polysaccharide containing galacturonic acid, reacting hydrolyzed collagen peptide with the polysaccharide containing galacturonic acid to prepare a wall material solution, homogenizing the glycerophosphorylcholine solution and the wall material solution, and performing spray drying to obtain the microcapsule. The microcapsule is applied to fruit juice beverages, oral liquid, solid beverages and tablets. By wrapping the glycerophosphorylcholine in the wall material, the problems that the glycerophosphorylcholine is easy to absorb moisture and poor in acid-base stability are solved.

The invention relates to the technical field of medical protection materials, and discloses an anti-allergy skin-friendly operating kit and a preparation technology, and the composite material of the operating kit comprises the following components by mass: 40-70 parts of cellulose-based non-woven fabric; 1 to 10 parts of polymethacryloyloxyethyl phosphorylcholine which is covalently grafted to the cellulose-based non-woven fabric; 20 to 50 parts of polylactic acid-quaternary ammonium salt copolymer; 5 to 15 parts of a polyurethane hot melt adhesive; the method comprises the following steps: grafting a PMPC molecular brush on the surface of a cellulose-based non-woven fabric to obtain a skin-friendly layer; carrying out coaxial electrostatic spinning and solvent treatment on the polylactic acid-quaternary ammonium salt copolymer to prepare a hollow nanofiber barrier layer; and finally hot-pressing and compounding the two layers through a polyurethane hot-melt adhesive. According to the invention, allergy is solved through surface grafting; the toxicity is avoided by using an intrinsic antibacterial polymer; the hollow fibers and the net film are compounded, so that the contradiction between water resistance and breathability is overcome, and the biological safety and comfort of the material are improved.

The invention provides a functional raw material composition. The functional raw material composition comprises a functional active component, a phosphorylcholine polymer, a polymer carrier, polyol, a cosolvent and water. The invention also provides a method for improving the stability and transdermal absorption of the functional active matter in the polymer carrier. The invention further provides application of the functional raw material composition. The method for improving the stability and the transdermal absorption of the functional active matter in the polymer carrier is simple in preparation process, high in wrapping efficiency, high in safety, stable in product and controllable in active matter content, and the stability and the transdermal absorption effect of the embedded functional active matter can be remarkably improved.

The invention relates to an endothelialization-promoting antifouling developing coating material as well as a preparation method and application thereof. The endothelialization-promoting antifouling developing coating material is obtained by reacting a siloxane-modified developing agent with a modified phosphorylcholine polymer; the modified phosphorylcholine polymer is obtained by copolymerization of a double-bond-containing monomer, and the double-bond-containing monomer comprises a combination of a double-bond-containing phosphorylcholine monomer, an endothelialization-promoting monomer and a siloxane monomer. According to the endothelialization-promoting antifouling developing coating material disclosed by the invention, a siloxane-modified developing agent is connected with a modified phosphorylcholine polymer. The siloxane-modified developing agent improves the developing function, and the modified phosphorylcholine polymer provides antifouling and endothelialization promoting functions, so that a composite coating with antifouling, developing and endothelialization promoting functions is formed.

Provided is a medical suture thread as a multifilament, which is formed easily bendable and ensuring favorable operability. The medical suture thread 100 includes a core thread 110 and an outer thread 120. The core thread 110 includes multiple twisted ultrafine threads 111, and is arranged at a center portion of the medical suture thread 100. In the ultrafine thread 111, an inner-filament cover layer 112 made of 2-methacryloyloxyethyl phosphorylcholine (MPC) is formed on an outer surface of a filament 111a. The outer thread 120 is formed to be braided with multiple ultrafine threads 121, and covers an outer surface of the core thread 110. In the ultrafine thread 121, an outer-filament cover layer 122 made of MPC is formed on an outer surface of a filament 121a.

The invention discloses an acute kidney injury nuclear magnetic resonance detection contrast agent as well as a preparation method and application thereof. The lipidosome comprises a first lipid component and a second lipid component, the first lipid component is any one of 1, 2-dipalmitoyl-sn-glycerol-3-phosphorylcholine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine and distearoyl phosphatidylcholine, and the second lipid component is a sterol derivative, and the first lipid component is any one of 1, 2-dipalmitoyl-sn-glycerol-3-phosphorylcholine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine and distearoyl phosphatidylcholine. The molar ratio of the first lipid component to the second lipid component is (1-3): 1. According to the invention, all organic free radicals are used for replacing gadolinium ions, so that renal toxicity and systemic fibrosis risks caused by metal accumulation are eliminated, and the method is especially suitable for imaging of patients with renal insufficiency. The material synthesis process is simple, and the cost is controllable. In addition, the system is seamlessly compatible with clinical 3.0 T MRI equipment, additional hardware transformation is not needed, and popularization and application of AKI bedside rapid imaging diagnosis can be directly promoted.

The invention belongs to the technical field of organic synthesis, and relates to a preparation method of N-palmitoyl-O-phosphorylcholine serine and a deuterated substance thereof. The N-palmitoyl-O-phosphorylcholine serine and the deuterated substance thereof are obtained by taking L-serine methyl ester hydrochloride and palmitic acid as raw materials through amidation reaction, phosphate esterification reaction, quaternization reaction, oxidation reaction, reduction reaction and the like. The invention provides an approach for industrial production of the N-palmitoyl-O-phosphorylcholine serine and the deuterated substance thereof, and is very important for standardization of the detection method of the N-palmitoyl-O-phosphorylcholine serine.

The invention provides 3D printing bio-ink as well as a preparation method and application thereof. The 3D printing bio-ink is prepared from the following components: methacrylic anhydride gelatin, oxidized hyaluronic acid, carboxymethyl chitosan and 2-methacryloyloxyethyl phosphorylcholine. By designing the specific composition of the 3D printing bio-ink, the 3D printing bio-ink which is good in printing performance, mechanical strength and electrical conductivity and high in cell survival rate after printing is prepared, and then a 3D printing stent with high cell-stent interaction is prepared and can be used for preparing a skin injury repair material.

The present invention relates to an ophthalmological composition, comprising at least one nicotinic acetylcholine receptor (nAChR) modulator, in particular varenicline, mecamylamine and derivatives, and / or at least one substance of the endogenous Kennedy metabolic pathways, as well as salts and derivatives or pharmaceutically acceptable salts of these substances, and choline-containing phospholipids, salts and derivatives of these substances. From these groups, particular preference is given to choline, phosphocholine, CDP-choline (citicoline), phosphatidylcholine (for example lecithin having a phosphatidylcholine content ≥ 80 wt.%, for example soy lecithin), ethanolamine, phosphoethanolamine, CDP-ethanolamine, phosphatidylethanolamine, L-α-glycerylphosphorylcholine, phosphatidylcholine, and phosphatidylethanolamine.

A complex consisting of lipoic acid or a salt thereof, a chelating agent such as a salt of ethylene diamine tetraacetic acid (EDTA) or analogous compounds and an ester of ascorbic acid with long-chain fatty acids, in particular ascorbyl palmitate inhibits the pigmentation of teeth induced by chlorhexidine and salts thereof. In addition to the depigmenting complex, the formulations of the invention, in the form of gels, mouthwashes, toothpastes or periodontal sprays, may contain other ingredients such as hyaluronic acid or hyaluronates, glycerophosphocholine, sweeteners, flavourings, buffering agents, viscosifying agents, mucoadhesive and filming agents, solvents, co-solvents, surfactants.

The present invention discloses a silicon monoxide nanomaterial and a preparation method thereof, belonging to the technical field of nanomaterials. The silicon monoxide nanomaterial comprises the following raw materials in parts by weight: metal silicon powder: 80 - 120 parts, silicon dioxide powder: 20 - 40 parts, binder: 0.5 - 3 parts, surfactant: 2 - 8 parts; in the present invention, intermediate 1 is prepared by the substitution reaction of 3 - allyl - 2 - hydroxybenzaldehyde and epichlorohydrin, then intermediate 2 is prepared by the ring - opening reaction of intermediate 1 and n - decanol, then intermediate 3 is prepared by the sulfonation reaction of intermediate 2 and 1,3 - propane sultone, and finally the surfactant is prepared by the polymerization reaction of 2 - methacryloyloxyethyl phosphorylcholine, 2 - acrylamide - 2 - methylpropanesulfonic acid and intermediate 3. The silicon monoxide nanomaterial prepared by the present invention has a high initial Coulomb efficiency and good cycle performance.

Provided herein are pharmaceutical compositions and formulations of a conjugate comprising a first protein, such as an anti-VEGF antibody, conjugated to a phosphorylcholine-containing polymer, and a second protein that is not conjugated to a phosphorylcholine-containing polymer. The second protein can be the same as the first protein, or can be different. In some embodiments, the pH of the formulation is different from the isoelectric point (pI) of the second protein so as to prevent or reduce turbidity of the formulation. Also provided are methods of preparing the formulations, methods of use thereof, and kits with pre-filled syringes containing the formulations.

The application belongs to the technical field of medical biomaterials, and particularly relates to an interpenetrating network polymer based on phosphorylcholine polymer and a preparation method and application thereof. The application provides a sequential interpenetrating network method, which comprises the following steps: preparing a monomer infiltration solution containing phosphorylcholine monomer, polyethylene glycol methacrylate, dimethylaminoethyl methacrylate, butyl methacrylate, hydroxyethyl methacrylate, ethylene glycol methacrylate, a crosslinking agent and an initiator; dipping a high-molecular polymer matrix into the monomer infiltration solution, and performing ultrasonic oscillation treatment to promote the infiltration of monomers into the interior of the matrix; and performing a polymerization reaction to obtain a final product after washing; the material prepared by the application has excellent thermal stability, excellent swelling performance, intelligent pH response drug release capacity and biocompatibility, and is suitable for the fields of biological medicine and cosmetics.

Provided are a difluoroalkylphosphorylcholine compound and an intermediate thereof. Specifically provided is a compound represented by formula I or a salt thereof. The compound represented by formula I or a salt thereof exhibits good surface activity, good solubility and good environmental friendliness and biofriendliness, is easy to store at a high concentration and convenient to transport, and has good application prospects.

The invention provides an anti-coagulation coating. The anti-coagulation coating comprises an anti-coagulation component and a cross-linking agent, the preparation method of the anti-coagulation coating comprises the following steps: plasma activation: carrying out surface activation treatment on the surface of the conduit by adopting plasma; preparing a surface anti-coagulation coating: firstly preparing an anti-coagulation solution, immersing the catheter in the anti-coagulation solution containing phosphorylcholine, placing the catheter at room temperature after dip-coating, then placing the catheter in a curing box for curing, and taking out the catheter after the catheter is cooled to the room temperature, so as to prepare the catheter with the anti-coagulation coating containing phosphorylcholine; according to the anticoagulant coating, complications such as thrombus and fibrin sheath are reduced, the safety of a product is improved, anaphylactic reaction caused by drugs and heparin is avoided, and a passive anticoagulation mode is adopted, so that the blood coagulation capacity of a patient cannot be reduced, and the risk that a wound cannot be healed can be effectively reduced.

The invention relates to a magnesium- aluminium layered double hydroxide (Mg-Al LDH) based filler product comprising boron and functionalised with phosphocholine chloride calcium salt tetrahydrate (PC), the synthesis method of this filler product, and obtaining a new material by preparing a composite material of this filler product, which has antibacterial activity, with a thermoplastic polymer or thermosetting polymer. In the production of the composite material that is the subject of the invention, as the polymer, preferably unsaturated polyester resin (DPes) is used. The composite material comprising the filler product of the invention has the feature of preventing bacterial adhesion / biofilm formation. Said material has the potential to be used for various applications, including medical devices, industrial processes, food production, storage and sales areas, food contact surfaces, areas requiring cleaning and hygiene, and different surface materials.

The present invention provides a single-stranded nucleic acid adsorption inhibitor containing one or more polymers selected from the group A: [group A] Polymer A1: a copolymer containing a structural unit (a) derived from 2-(meth) acryloyloxyethyl phosphorylcholine and a structural unit (b) derived from a C2-C6 alkyl (meth) acrylate having two or more hydroxyl groups as substituents; polymer A2: a copolymer containing the constituent unit (a) and a constituent unit (c) derived from a polyethylene glycol (meth) acrylate; and polymer A3: a copolymer containing the constituent unit (a) and a constituent unit (d) derived from a C1-C6 alkyl (meth) acrylate having a phenyl group or a phenoxy group as a substituent.

The invention relates to a ureteral stent with a zwitterionic coating and a preparation method thereof.The ureteral stent comprises a stent body and the zwitterionic coating covering the stent body, the zwitterionic coating is formed by a zwitterionic coating composition, and the zwitterionic coating composition comprises a homopolymer or copolymer of zwitterionic and a solvent; the photocuring layer is covalently bonded on the surface of the bracket in a photocuring manner; the zwitterion is selected from phosphorylcholine; the zwitterionic copolymer is at least formed by copolymerizing a phosphorylcholine monomer and a hydrophilic monomer; or the zwitterionic copolymer is at least formed by copolymerizing the phosphorylcholine monomer, the hydrophilic monomer and the photosensitive monomer. The copolymer / homopolymer of zwitter-ions is covalently fixed on the surface of a base material in a photo-initiation mode, the coating is firm and stable, the coating with hydrophilic lubrication and zwitter-ions simultaneously can be constructed on the surface, the high lubricity function and the high anti-crystallization function are both considered, and the efficient anti-crystallization effect is synergistically achieved.

The present invention provides therapeutic and / or prophylactic treatments against leishmaniasis in non-human mammals in need of such treatment, said treatments comprising administering oleyl phosphocholine to said non-human mammal. The invention also relates to veterinary (pharmaceutical) compositions adapted, suitable and / or intended for use in these treatments.